第一医药(600833) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 124 million and 185 million CNY, an increase of 34.72 million to 95.72 million CNY compared to the previous year, representing a year-on-year increase of 38.90% to 107.22%[4] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 6 million and 9 million CNY, a decrease of 1.88 million to 4.88 million CNY compared to the previous year, indicating a year-on-year decline of 17.25% to 44.83%[4] - In the previous year, the company achieved a total profit of 117.51 million CNY and a net profit attributable to shareholders of the parent company of 89.28 million CNY[6] Factors Influencing Profit - The increase in net profit is primarily due to compensation received for property expropriation during the reporting period[7] - The decline in net profit excluding non-recurring gains and losses is attributed to intensified competition in the pharmaceutical industry and the impact of new store openings, which are still in the growth phase[7] Earnings Forecast Validity - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant[8] - The company emphasizes that there are no significant uncertainties affecting the accuracy of the earnings forecast[8] - The data provided in the earnings forecast is preliminary and the final financial data will be disclosed in the official 2024 annual report[9]